Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?
Driving revenue growth and earnings growth are two different things.
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?
Overview
Teva Pharmaceutical Industries (NYSE: TEVA) has clawed back from the brink like few drugmakers have. After a long stretch of poor performance, a company once buried under debt, patent cliffs, and litigation is now up by 97% in the last 12 months. The bull case credits its expanding biosimilars lineup, and that quickly growing segment could mean the stock has more room to run.
Still, a recently risen share price and a growing product line are not the same as a stock worth buying today. Will biosimilars truly move the needle for a business this size? Is the easy money already made, or is there more to come? Let's find out.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
- Is it too late to buy SpaceX’s stock? Here’s how Tesla’s did after one day — and five years.
- Brent Oil Drops Below $90 as the U.S. Closes in on a Peace Deal With Iran. What it Means for Oil Stocks.
- Adobe’s CFO is departing for Marvell. And it’s one more reason for investors to choose chips over software.
